Advertorial

Expert view: Understanding the fast-evolving immune-oncology landscape

Posted: 12 December 2019 | | No comments yet

The number of immuno-oncology active agents has seen a tremendous boost during the past three years. The 2019 global immuno-oncology pipeline consists of almost 3,900 agents, making immuno-oncology discovery very attractive.

 It encompasses T cell-targeted immunomodulators, cancer vaccines, cell therapy, oncolytic viruses, CD3-targeted bispecific antibodies as well as immunostimulators, such as agonists of the innate immune pathway.

A recent report in Nature Reviews Drug Discovery (Tang et al, 2019) stated that the immuno-oncology pipeline increased by 91 percent for active agents between 2017 and 2019. Cell therapy experienced the largest growth (800 more drugs in the pipe), while oncolytic viruses experienced the smallest (only 31 new agents). Immuno-oncology-related agents are included in 66 percent of all active trials, which evidences the continuous expansion of immuno-oncology drugs. Finally, innovation is driven by the growing number of new biological targets, of which there has been a 78 percent increase in the past two years.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Cisbio Bioassays

Send this to a friend